<DOC>
	<DOCNO>NCT00889590</DOCNO>
	<brief_summary>This multicenter , randomise phase II trial patient high risk GCT . Primary objective : - Determine adjuvant zoledronic acid improve 2 year recurrence rate 'high risk ' GCT compare standard care Secondary objective : - Determine relapse free survival - Evaluate usefulness bone remodelling marker diagnose monitoring GCT</brief_summary>
	<brief_title>Adjuvant Zoledronic Acid High Risk Giant Cell Tumour Bone ( GCT )</brief_title>
	<detailed_description>GCT potentially malignant tumour present locally destructive osteolytic lesion . The high risk GCT characterize high recurrence rate around 40-45 % . Zoledronic acid potent inhibitor osteolysis capable induce osteoclast stromal cell apoptosis , make attractive adjuvant treatment 'high risk ' GCT order improve clinical outcome reduce recurrence rate .</detailed_description>
	<mesh_term>Giant Cell Tumors</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Giant Cell Tumor Bone</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Signed write informed consent Male female &gt; 18 year age Histologically proven GCT treat surgery High risk GCT define minimal one following : Recurrent GCT GCT locate pelvis , sacrum , spine , distal ulna growth soft tissue GCT grade III Pathological fracture GCT Absence local adjuvant therapy ( cryosurgery phenol instillation ) Neutrophils &gt; 1.5x109/L , platelet &gt; 100x109/L , Hb &gt; 6 mmol/l Bilirubin level &lt; 1.5 x ULN ASAT ALAT &lt; 2.5 x ULN Adequate renal function define : serum creatinine clearance &gt; 60 cc/min Expected adequacy followup Unresectable metastatic GCT grade IV GCT Prior bisphosphonate usage , except preoperative treatment zoledronic acid 3 month surgery Other previous malignancy within 5 year , exception history previous basal cell carcinoma skin preinvasive carcinoma cervix Known hypersensitivity reaction component treatment Pregnancy lactate Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>GCT</keyword>
	<keyword>Bisfosfonates</keyword>
</DOC>